EUCTR2013-005362-19-DE进行中（未招募）1 期
Therapy of antibody-mediated autoimmune diseases by Bortezomib (TAVAB) - TAVAB
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-age 18 - 75 years at screening
- •-ability to give written consent, informed wirtten consent
- •-negative pregnancy test at screening
- •-therapy-refractory Myasthenia Gravis (generalized) or Systemic Lupus Erythematosus or Rheumatoid Arthritis
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 14
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 4
排除标准
- •-known intolerability to Bortezomib
- •-participation in another interventional trial within the last 3 months
- •-heart or kidney insufficiency
- •- liver cirrhosis
研究者
相似试验
已完成
不适用
Clinical trial for the treatment of autoimmune cytopenias by using rituximabautoimmune cytopeniasJPRN-UMIN000021446Department of Pediatrics, Kanazawa University10
招募中
不适用
'Smoldering' autoimmune inflammatory pathophysiology in epilepsiesEpilepsyJPRN-UMIN000006800Kyoto University School of Medicine50
已完成
不适用
Immunogenetic and therapeutic aspects of Autoimmune HepatitisNL-OMON44835Vrije Universiteit Medisch Centrum2,000
已完成
不适用
ASER ASSISTED IMMUNOTHERAPY-C50 Malignant neoplasm of breastMalignant neoplasm of breastC50PER-091-09IMMUNOPHOTONICS / THE SOURCE SAC,10
招募中
不适用
Towards prevention of chronic auto-immune disease: dominant B-cell receptor clones predict the onset of rheumatoid arthritisrheumatoid arthritisNL-OMON45295Academisch Medisch Centrum75